MAM
Haldiram Foods appoints Nitesh G as VP of sales
MUMBAI: After decades of driving sales across the FMCG sector, a seasoned veteran is embarking on a new chapter.
Nitesh G, a stalwart in the fast-moving consumer goods industry and former chief business officer, has taken on the mantle of vice president of sales at Haldiram Foods International Ltd. Known for his strategic acumen and unmatched expertise, Nitesh’s appointment in December 2024 signals a bold move by the iconic Indian brand to further solidify its leadership in the competitive food market.
Nitesh announced his new role on LinkedIn, stating, “I’m happy to share that I’m starting a new position as Vice President of Sales at Haldiram Foods International Ltd.”
With over two decades in the fast-moving consumer goods (FMCG) sector, Nitesh brings a wealth of experience to Haldiram’s. Prior to this appointment, he served as CBO at Mrs. Bectors Food Specialities Ltd, overseeing brands such as Cremica and English Oven.
Nitesh’s career includes significant roles at Cream Bell Ice Cream, Britannia Industries Limited, and Vodafone, where he honed his expertise in sales and business development.
In his new position, Nitesh will spearhead Haldiram’s sales strategies, aiming to expand market reach and strengthen the brand’s presence in the competitive snack-food industry.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
